Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532860 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL3155105 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL9821196 | 0.95 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL10405140 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL11513286 | 0.87 | LMNA (0.66) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL11553488 | 0.86 | LMNA (0.71) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL19559404 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL9850874 | 0.82 | TP53 (0.70) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL9670417 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1TP53LMNATSHR | |
| SCHEMBL563022 | 0.79 | TP53 (0.67) | SMN1; SMN2ALDH1A1TP53LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382203-B2 | N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2016-07-05 | — | — | US | disclosed |
| US-9382203-B2 | N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2016-07-05 | — | — | US | disclosed |
| US-9382203-B2 | N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2016-07-05 | — | — | US | disclosed |
| US-9382203-B2 | N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2016-07-05 | — | — | US | disclosed |
| US-9102615-B2 | N-Carbamoylmethy1-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2015-08-11 | — | — | US | disclosed |
| US-9102615-B2 | N-Carbamoylmethy1-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2015-08-11 | — | — | US | disclosed |
| US-9102615-B2 | N-Carbamoylmethy1-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2015-08-11 | — | — | US | disclosed |
| US-9102615-B2 | N-Carbamoylmethy1-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2015-08-11 | — | — | US | disclosed |
| US-20150216846-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | JOINT STOCK COMPANY (JSC) "OLAINFARM" (LV) | 2015-08-06 | — | — | US | disclosed |
| US-20150216846-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | JOINT STOCK COMPANY (JSC) "OLAINFARM" (LV) | 2015-08-06 | — | — | US | disclosed |
| EP-2013166-B1 | N-CARBAMOYLMETHYL-4(R)-PHENYL-2-PYRROLIDINONE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE | AKCIJU SABIEDRIBA OLAINFARM (LV) | 2010-03-10 | — | — | EP | disclosed |
| US-20100022784-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | Joint Stock Company "Olainfarm" (LV) | 2010-01-28 | — | — | US | disclosed |
| US-20100022784-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | Joint Stock Company "Olainfarm" (LV) | 2010-01-28 | — | — | US | disclosed |
| US-20100022784-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | Joint Stock Company "Olainfarm" (LV) | 2010-01-28 | — | — | US | disclosed |
| CN-101448786-A | Preparation method and pharmaceutical application of N-carbamoylmethyl-4 -phenyl-2-pyrrolidone | Grigory Veinberg (LV) | 2009-06-03 | — | — | CN | disclosed |
| EP-2013166-A2 | N-CARBAMOYLMETHYL-4(R)-PHENYL-2-PYRROLIDINONE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE | Akciju Sabiedriba "Olainfarm" (LV) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007104780-A3 | N- CARBAMOYLMETHYL- 4- (R) -PHENYL-2-PYRR0LIDIN0NE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE | VEINBERG GRIGORY (LV) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007104781-A3 | METHOD FOR MANUFACTURING OF R-ENANTIOMER OF N-CARBAMOYLMETHYL-4-PHENYL-2-PYRROLIDONE | VEINBERG GRIGORY (LV) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007104781-A2 | METHOD FOR MANUFACTURING OF R-ENANTIOMER OF N-CARBAMOYLMETHYL-4-PHENYL-2-PYRROLIDONE | AKCIJU SABIEDRIBA 'OLAINFARM' (LV) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104780-A2 | N- CARBAMOYLMETHYL- 4- (R) -PHENYL-2-PYRR0LIDIN0NE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE | AKCIJU SABIEDRIBA 'OLAINFARM' (LV) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022784-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | PRMT6, CPS1, JMJD6 | SMN1; SMN2 1212/4885ALDH1A1 3160/4885TP53 3584/4885 |
| US-20150216846-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | PRMT6, CPS1, JMJD6 | SMN1; SMN2 1212/4885ALDH1A1 3160/4885TP53 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.